|
WO2020232154A2
|
|
Methods of treating cancer using chk1 inhibitors
|
|
WO2020198510A1
|
|
Methods of treating cancer with chk1 inhibitors
|
|
AU2019350581A1
|
|
Methods of treatment of cancer comprising Cdc7 inhibitors
|
|
WO2020041466A1
|
|
Platelet count-agnostic methods of treating myelofibrosis
|
|
WO2019165473A1
|
|
Methods of treatment of cancer comprising cdc7 inhibitors
|
|
CA3092079A1
|
|
Methods of treatment of cancer comprising chk1 inhibitors
|
|
CA3065803A1
|
|
Biomarkers and patient selection strategies
|
|
WO2018191299A1
|
|
Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
|
|
US2021077499A1
|
|
Chk1 (sra737)/parpi combination methods of inhibiting tumor growth
|
|
US2018042933A1
|
|
Treatment of ACVR1-mediated diseases
|
|
TW201617323A
|
|
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
|
